News
April 6, 2026 Research and Development
Pharma Foods Co., Ltd. Acquires Exclusive Rights to Advance First-in-Class Adrenomedullin Program for CADASIL Across Key Asian Markets
Pharma Foods Co., Ltd. (Head Office: Kyoto, Japan; President and CEO: Mujo Kim; hereinafter “the Company”) announced that it has entered into exclusive licensing agreements with Himuka AM Pharma Corp. (Head Office: Miyazaki, Japan) and the National Cerebral and Cardiovascular Center (Osaka, Japan; hereinafter: “NCVC”) to develop and commercialize human adrenomedullin as a potential first-in-class therapy for CADASIL.